Published in J Biol Chem on June 25, 1999
QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol (2003) 2.88
Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest (2001) 2.35
The proteoglycan bikunin has a defined sequence. Nat Chem Biol (2011) 2.14
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Heparan sulfate 6-O-endosulfatases: discrete in vivo activities and functional co-operativity. Biochem J (2006) 1.48
Structural analysis of bikunin glycosaminoglycan. J Am Chem Soc (2008) 1.37
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol (2010) 1.21
Specific heparan sulfate structures modulate FGF10-mediated submandibular gland epithelial morphogenesis and differentiation. J Biol Chem (2008) 1.14
SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene (2011) 1.11
Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J (2002) 1.07
Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics: insights into protein binding specificities. J Biol Chem (2009) 1.05
Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic and glucuronic acid-containing hexasaccharides. Anal Chem (2009) 1.01
'Heparin'--from anticoagulant drug into the new biology. Glycoconj J (2001) 1.01
Multimers of the fibroblast growth factor (FGF)-FGF receptor-saccharide complex are formed on long oligomers of heparin. Biochem J (2006) 1.00
Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost (2007) 1.00
Proteoglycan sequence. Mol Biosyst (2012) 0.98
The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance. Br J Pharmacol (2009) 0.96
Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery. Acta Biomater (2013) 0.90
Cooperative heparin-mediated oligomerization of fibroblast growth factor-1 (FGF1) precedes recruitment of FGFR2 to ternary complexes. Biophys J (2013) 0.90
Therapeutically targeting protein-glycan interactions. Br J Pharmacol (2009) 0.88
Fell-Muir Lecture: Heparan sulphate and the art of cell regulation: a polymer chain conducts the protein orchestra. Int J Exp Pathol (2015) 0.87
Heparan sulfate 2-O-sulfotransferase (Hs2st) and mouse development. Glycoconj J (2003) 0.85
Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I. J Biol Chem (2014) 0.82
Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion. Respir Res (2014) 0.82
Combined strong anion-exchange HPLC and PAGE approach for the purification of heparan sulphate oligosaccharides. Biochem J (2001) 0.82
Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. Biochem J (2003) 0.82
A computational approach for deciphering the organization of glycosaminoglycans. PLoS One (2010) 0.81
Molecular structure of heparan sulfate from Spalax. Implications of heparanase and hypoxia. J Biol Chem (2008) 0.79
The "in and out" of glucosamine 6-O-sulfation: the 6th sense of heparan sulfate. Glycoconj J (2016) 0.77
Glycomics approaches for the bioassay and structural analysis of heparin/heparan sulphates. Metabolites (2012) 0.76
Prevalence of lysosomal storage disorders. JAMA (1999) 9.06
Prevention of prolonged labour. Br Med J (1969) 7.37
Structure and function of heparan sulphate proteoglycans. Biochem J (1986) 2.78
Huntington disease-linked locus D4S111 exposed as the alpha-L-iduronidase gene. Somat Cell Mol Genet (1991) 2.23
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2007) 2.20
Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem (1992) 2.20
Control of morphology, cytoskeleton and migration by syndecan-4. J Cell Sci (1999) 2.17
Active management of labour and cephalopelvic disproportion. J Obstet Gynaecol Br Commonw (1970) 2.06
Paraquat poisoning in a pregnant woman. Br Med J (1968) 2.04
Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem (1998) 1.97
Chromosomal localization of ARSB, the gene for human N-acetylgalactosamine-4-sulphatase. Hum Genet (1989) 1.95
Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A (1990) 1.91
Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides. Biochem J (1985) 1.86
Mucous glycoproteins: a gel of a problem. Essays Biochem (1985) 1.82
Glycosaminoglycan synthesis by cultured human skin fibroblasts after transformation with simian virus 40. J Biol Chem (1977) 1.77
Liver heparan sulfate structure. A novel molecular design. J Biol Chem (1994) 1.76
A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology (1999) 1.67
Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity. Biochem J (1986) 1.61
Genetic mapping of new RFLPs at Xq27-q28. Genomics (1991) 1.60
Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry (1990) 1.60
The composition of tracheal mucus and the nervous control of its secretion in the cat. Proc R Soc Lond B Biol Sci (1975) 1.58
Structure of a human lysosomal sulfatase. Structure (1997) 1.57
Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta (2005) 1.56
The molecular phenotype of heparan sulfate in the Hs2st-/- mutant mouse. J Biol Chem (2001) 1.55
Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat (1995) 1.54
Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Hum Mutat (2001) 1.52
Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem (1994) 1.52
Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties. Biochem J (1990) 1.50
Human alpha-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci U S A (1991) 1.48
The molecular-weight distribution of glycosaminoglycans. Biochem J (1973) 1.48
alpha-L-iduronidase, beta-D-glucuronidase, and 2-sulfo-L-iduronate 2-sulfatase: preparation and characterization of radioactive substrates from heparin. Carbohydr Res (1979) 1.45
Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem (1997) 1.43
High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal Biochem (1982) 1.43
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord (2003) 1.41
The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol Chem (1997) 1.41
Enzymatic diagnosis of the mucopolysaccharidoses: experience of 96 cases diagnosed in a five-year period. Med J Aust (1982) 1.41
Coexistence of Gaucher disease type 1 and Joubert syndrome. J Med Genet (1998) 1.40
Violence research. Science (1994) 1.40
Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem (1994) 1.40
Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet (2009) 1.39
Human alpha-L-iduronidase. 1. Purification, monoclonal antibody production, native and subunit molecular mass. Eur J Biochem (1985) 1.39
Distribution of iduronate 2-sulphate residues in heparan sulphate. Evidence for an ordered polymeric structure. Biochem J (1991) 1.36
The alkaline cleavage and borohydride reduction of cartilage proteoglycan. Biochem J (1973) 1.36
Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet (2001) 1.36
Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol (1998) 1.35
Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology (2000) 1.34
Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values. Biochem J (1987) 1.34
Human liver sulphamate sulphohydrolase. Determinations of native protein and subunit Mr values and influence of substrate agylcone structure on catalytic properties. Biochem J (1986) 1.33
Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes. Am J Hum Genet (1994) 1.33
Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase. Biochem J (1992) 1.32
Structure and sequence of the human alpha-L-iduronidase gene. Genomics (1992) 1.32
Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem (2001) 1.28
A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes. Clin Chim Acta (1979) 1.27
A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proc Natl Acad Sci U S A (1999) 1.27
The alkali-labile linkage between keratan sulphate and protein. Biochem J (1974) 1.27
Psychiatric diagnoses in adolescents seropositive for the human immunodeficiency virus. Arch Pediatr Adolesc Med (2000) 1.26
Human alpha-L-iduronidase. 2. Catalytic properties. Eur J Biochem (1985) 1.26
Proteoglycans in haemopoietic cells. Biochim Biophys Acta (1990) 1.24
Specific association of iduronic acid-rich dermatan sulphate with the extracellular matrix of human skin fibroblasts cultured on collagen gels. Biochem J (1983) 1.24
Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J Biol Chem (1998) 1.24
Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest (1996) 1.24
Immunopurification and characterization of human alpha-L-iduronidase with the use of monoclonal antibodies. Biochem J (1989) 1.24
Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B). Hum Mol Genet (1996) 1.22
The diagnosis of the Sanfilippo C syndrome, using monosaccharide and oligosaccharide substrates to assay acetyl-CoA: 2-amino-2-deoxy-alpha-glucoside N-acetyltransferase activity. Clin Chim Acta (1981) 1.22
Regulation of haemopoiesis in long-term bone marrow cultures. IV. Glycosaminoglycan synthesis and the stimulation of haemopoiesis by beta-D-xylosides. J Cell Biol (1983) 1.22
Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem (2001) 1.22
Human liver N-acetylglucosamine-6-sulphate sulphatase. Purification and characterization. Biochem J (1987) 1.21
Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem (1994) 1.21
Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme. Int J Biochem (1992) 1.21
Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr Suppl (2005) 1.18
Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet (1994) 1.18
Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes. Am J Hum Genet (1993) 1.18
Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet (1999) 1.17
Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme. Biochem J (1993) 1.17
Diagnosis of Sanfilippo type A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate. Clin Chim Acta (1982) 1.17
A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype. Hum Mutat (1992) 1.17
A temperature-sensitive mutation of Crygs in the murine Opj cataract. J Biol Chem (2000) 1.16
Human liver N-acetylglucosamine-6-sulphate sulphatase. Catalytic properties. Biochem J (1987) 1.16
Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res (1994) 1.16
Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome. Hum Genet (1991) 1.15
Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem (1998) 1.14
Molecular cloning of the major cell surface heparan sulfate proteoglycan from rat liver. J Biol Chem (1992) 1.13
Biochemical discrimination of Hurler and Scheie syndromes. Clin Sci (Lond) (1979) 1.13
Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet (1995) 1.13
alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Hum Mutat (1992) 1.12
Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol (2007) 1.12
Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr Res (2000) 1.12
Heparan sulphate. Int J Biochem Cell Biol (1997) 1.12
Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol (2007) 1.11
Identification of two binding sites for wheat-germ agglutinin on polylactosamine-type oligosaccharides. Biochem J (1985) 1.11
alpha-L-Iduronidase deficiency in mucopolysaccharidosis type I against a radiolabelled sulfated disaccharide substrate derived from dermatan sulfate. Clin Genet (1984) 1.10